AUTHOR=Brault Julie , Liu Taylor , Liu Siyuan , Lawson Amanda , Choi Uimook , Kozhushko Nikita , Bzhilyanskaya Vera , Pavel-Dinu Mara , Meis Ronald J. , Eckhaus Michael A. , Burkett Sandra S. , Bosticardo Marita , Kleinstiver Benjamin P. , Notarangelo Luigi D. , Lazzarotto Cicera R. , Tsai Shengdar Q. , Wu Xiaolin , Dahl Gary A. , Porteus Matthew H. , Malech Harry L. , De Ravin Suk See 

TITLE=CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1067417

DOI=10.3389/fimmu.2022.1067417

ISSN=1664-3224

ABSTRACT=<sec><title>Introduction</title><p><italic>Ex vivo</italic> gene therapy for treatment of Inborn errors of Immunity (IEIs) have demonstrated significant clinical benefit in multiple Phase I/II clinical trials. Current approaches rely on engineered retroviral vectors to randomly integrate copy(s) of gene-of-interest in autologous hematopoietic stem/progenitor cells (HSPCs) genome permanently to provide gene function in transduced HSPCs and their progenies. To circumvent concerns related to potential genotoxicities due to the random vector integrations in HSPCs, targeted correction with CRISPR-Cas9-based genome editing offers improved precision for functional correction of multiple IEIs. </p></sec><sec><title>Methods</title><p>We compare the two approaches for integration of <italic>IL2RG</italic> transgene for functional correction of HSPCs from patients with X-linked Severe Combined Immunodeficiency (SCID-X1 or XSCID); delivery <italic>via</italic> current clinical lentivector (LV)-<italic>IL2RG</italic> versus targeted insertion (TI) of <italic>IL2RG via</italic> homology-directed repair (HDR) when using an adeno-associated virus (AAV)-<italic>IL2RG</italic> donor following double-strand DNA break at the endogenous <italic>IL2RG</italic> locus. </p></sec><sec><title>Results and discussion</title><p><italic>In vitro</italic> differentiation of LV- or TI-treated XSCID HSPCs similarly overcome differentiation block into Pre-T-I and Pre-T-II lymphocytes but we observed significantly superior development of NK cells when corrected by TI (40.7% versus 4.1%, p = 0.0099). Transplants into immunodeficient mice demonstrated robust engraftment (8.1% and 23.3% in bone marrow) for LV- and TI-<italic>IL2RG</italic> HSPCs with efficient T cell development following TI-<italic>IL2RG</italic> in all four patients’ HSPCs. Extensive specificity analysis of CRISPR-Cas9 editing with rhAmpSeq covering 82 predicted off-target sites found no evidence of indels in edited cells before (<italic>in vitro</italic>) or following transplant, in stark contrast to LV’s non-targeted vector integration sites. Together, the improved efficiency and safety of <italic>IL2RG</italic> correction <italic>via</italic> CRISPR-Cas9-based TI approach provides a strong rationale for a clinical trial for treatment of XSCID patients.</p></sec>